Vedanta Biosciences Confirms Phase 3 RESTORATiVE303 Study of VE303 Will Proceed as Planned Following Interim Analysis
Vedanta Biosciences, a late clinical-stage company focused on developing microbiome-based oral therapies for gastrointestinal diseases, has announced encouraging progress in its pivotal Phase 3 clinical trial evaluating VE303 for the prevention of recurrent Clostridioides difficile infection (CDI). The update follows the completion of the first prespecified interim analysis conducted by the study’s independent Data Monitoring Committee (DMC), which recommended that the trial proceed without any modifications.
The Phase 3 study, known as RESTORATiVE303, is designed to assess the safety and efficacy of VE303 in patients who have experienced one or more recurrences of CDI. Recurrent CDI represents a significant clinical challenge, as patients who have already suffered an initial infection are at a substantially higher risk of experiencing subsequent episodes. These recurrences can lead to prolonged illness, increased healthcare utilization, and diminished quality of life, highlighting the urgent need for effective preventive therapies.
The interim analysis was triggered after approximately 50% of the planned patient population—specifically individuals with at least one recurrence of CDI at baseline—reached the Week 8 primary efficacy endpoint. This milestone allowed the DMC to conduct an unblinded evaluation of accumulated trial data, including both safety and efficacy outcomes. Such interim analyses are a standard component of large, late-stage clinical trials, providing an opportunity to ensure that the study is progressing as expected and that participants are not exposed to unnecessary risk.
Following its review, the DMC concluded that the efficacy observed to date exceeded the predefined futility threshold. In clinical trial design, a futility threshold is used to determine whether it is unlikely for a study to meet its primary endpoint based on interim data. Surpassing this threshold indicates that the therapy is demonstrating sufficient promise to justify continued evaluation. In addition to these positive efficacy signals, the committee reported that no significant adverse events or new safety concerns had emerged during the study period.
Based on these findings, the DMC recommended that the RESTORATiVE303 trial continue as originally planned, without any changes to the study protocol. This outcome is an important validation of both the trial design and the therapeutic potential of VE303, reinforcing confidence in the program as it advances toward completion.
VE303 is part of Vedanta’s broader effort to harness the human microbiome for therapeutic purposes. Unlike traditional antibiotics, which can disrupt the balance of beneficial bacteria in the gut, microbiome-based therapies aim to restore a healthy microbial ecosystem. In the case of CDI, this approach is particularly relevant, as the infection is often associated with antibiotic-induced disruption of the gut microbiota. By reintroducing beneficial bacterial strains, VE303 is intended to help prevent recurrence by reestablishing colonization resistance against harmful pathogens.
Looking ahead, Vedanta Biosciences has outlined several key milestones for the RESTORATiVE303 trial. The company expects to complete patient enrollment in the second half of 2026. The study is currently being conducted across more than 150 clinical sites in approximately 20 countries, reflecting a broad and diverse patient population. This global footprint is expected to support the generation of robust and generalizable data.
In addition to completing enrollment, a second interim analysis is planned for early in the second half of 2026. This upcoming analysis will provide another opportunity to evaluate the therapy’s performance and further inform the study’s progress. If the trial continues to demonstrate positive results, it could pave the way for regulatory submissions and eventual commercialization.
The continuation of the RESTORATiVE303 trial without modification represents a meaningful step forward in the development of VE303. For patients with recurrent CDI, who often face limited treatment options and a high risk of relapse, the prospect of a safe and effective preventive therapy is particularly significant. As the study progresses, the medical community will be closely watching for additional data that could confirm the potential of this microbiome-based approach to transform the management of this challenging condition.
About RESTORATiVE303
RESTORATiVE303 is a randomized, double-blind, placebo-controlled, multinational Phase 3 clinical trial evaluating the safety and efficacy of VE303 in patients at high risk for recurrence of Clostridioides difficile infection (CDI) following a course of antibiotics for a prior CDI episode. The primary endpoint is the CDI recurrence rate at Week 8 in the VE303 and placebo groups. Participants are randomized 2:1 to receive a 14-day course of VE303 or matching placebo.
The study is enrolling patients who are experiencing recurrent CDI, including many with first recurrence and a significant proportion receiving fidaxomicin for their qualifying CDI episode, reflecting the evolving standard of care in CDI management. The RESTORATiVE303 trial is intended to form the basis for a Biologics License Application (BLA) to be submitted to the U.S. Food and Drug Administration (FDA).
The Data Monitoring Committee (DMC) is an independent committee of clinical, scientific, and biostatistical experts who have no affiliation with Vedanta Biosciences. Consistent with standard practice for blinded, controlled trials, the DMC is the only body with access to unblinded interim data. Its mandate is to review accumulating safety and efficacy data at prespecified intervals and to recommend to the sponsor whether the trial should continue as planned, be modified, or be stopped. A recommendation to continue the study as planned indicates that the data reviewed are within the prespecified statistical boundaries required to complete the trial with the protocol-defined sample size and power to detect the primary endpoint.
About VE303
VE303 is an orally administered, potential first-in-class live biotherapeutic product (LBP) for the prevention of recurrent Clostridioides difficile infection (CDI). It consists of a defined bacterial consortium of eight strains that were rationally selected using Vedanta’s product engine. VE303 is produced from pure, clonal bacterial cell banks, which yield a standardized drug product in powdered form and bypass the need to rely on donor fecal material of inconsistent composition.
In the Phase 2 CONSORTiUM study, high-dose VE303 achieved a 30.5% adjusted absolute risk reduction in CDI recurrence versus placebo, representing a greater than 80% reduction in the odds of recurrence. VE303 has received Orphan Drug Designation (2017) and Fast Track Designation (2023) from the FDA. This project has been funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A5012C00177.
About Recurrent C. difficile Infection
Clostridioides difficile infection is a potentially life-threatening gastrointestinal infection affecting up to 175,000 patients annually in the United States, resulting in approximately 20,000 deaths each year. Patients who experience an initial CDI episode are at significant risk of recurrence, with each recurrence increasing the likelihood of subsequent episodes. Recurrent CDI is associated with substantial morbidity, prolonged hospitalization, and diminished quality of life. There remains a significant unmet need for safe and effective therapies that address the underlying dysbiosis driving recurrence.
About Vedanta Biosciences
Vedanta Biosciences is a late clinical-stage biopharmaceutical company developing a new category of microbiome-based oral therapies for gastrointestinal diseases. Vedanta’s lead program, VE303, is currently being evaluated in the global Phase 3 RESTORATiVE303 registrational study for the prevention of recurrent C. difficile infection.
Source Link:https://www.businesswire.com/
